Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I open-label study of RO7428731 in EGFRvIII-positive glioblastoma
NL-OMON54263Phase 1Recruiting
- Sponsor
- Roche
- Start
- Dec 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of RO7428731 in glioblastoma (GBM) (4 arms), sponsored by Roche. Primary endpoints: Safety and tolerability of RO7428731 and Maximum tolerated dose. Started Dec 2022; status: recruiting.
02
Drugs
RO7428731
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON54263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54263.